Tecarfarin

Synonyms: ATI-5923
Tecarfarin (ATI-5923) 是一种具有口服活性的 VKOR 抑制剂,对 VKORC1 的 IC50 为 0.67 μM,可通过阻断维生素 K 依赖性凝血因子 II、VII、IX、X 的翻译后修饰来降低其水平与活性,从而延长凝血酶原时间、减弱静脉与动脉血栓形成、增加耳切口出血量,并具有可逆的抗凝作用,可用于动脉和静脉血栓形成以及其他需要抗凝的疾病相关研究。
产品编号: MS-W12381 纯度: 98.65% CAS No.: 867257-26-9 分子式: C21H14F6O5 分子量: 460.32
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价

产品描述

Tecarfarin (ATI-5923) 是一种具有口服活性的 VKOR 抑制剂,对 VKORC1 的 IC50 为 0.67 μM,可通过阻断维生素 K 依赖性凝血因子 II、VII、IX、X 的翻译后修饰来降低其水平与活性,从而延长凝血酶原时间、减弱静脉与动脉血栓形成、增加耳切口出血量,并具有可逆的抗凝作用,可用于动脉和静脉血栓形成以及其他需要抗凝的疾病相关研究。

生物实验数据

生物活性 Tecarfarin (ATI-5923) is an orally active VKOR inhibitor with an IC50 of 0.67 μM against VKORC1 that reduces the levels and activity of vitamin K-dependent coagulation factors II, VII, IX, and X by blocking their post-translational modification, thereby prolonging prothrombin time, attenuating venous and arterial thrombosis, increasing ear incision bleeding, and exerting reversible anticoagulant effects, and it can be used in research related to arterial and venous thrombosis and other diseases requiring anticoagulation.
IC50 & Target

VKOR

体外研究
(In Vitro)

Tecarfarin 可抑制转染细胞中 CYP2C9 介导的代谢。
Tecarfarin (0.01-100 μM; 20 min) 可强效抑制混合人肝微粒体中的 VKORC1 活性,其 IC50 为 0.67 μM;该物质作为非竞争性抑制剂,对应的 Ki 值分别为 0.49 μM 和 0.63 μM (分别从斜率和纵轴截距算出的两个计算值)。

体内研究
(In Vivo)

Tecarfarin (0.5 mg/kg;口服;每日一次;连续 6 天) 可选择性降低雌性比格犬体内维生素 K 依赖性凝血因子水平,并将 PT 延长 3.1 倍。
Tecarfarin (0.05-0.5 mg/kg;口服;每日;4-7 天) 可使血管受电损伤且狭窄的混种犬的动脉闭塞性血栓形成时间和静脉闭塞性血栓形成时间分别延长 57% 和 119%。
Tecarfarin (1 mg/kg;口服;每日 1 次;连续 2 天) 在新西兰白兔中可使 INR 达到 2.1,并使静脉血栓形成率分别降低 89% (放射性法) 和 82% (称重法),与生理盐水对照组相比,出血情况无统计学意义的升高。
Tecarfarin (0.1-0.2 mg/kg;静脉注射;持续输注;每疗程给药 9 天) 可在比格犬中产生剂量依赖性抗凝作用。
Tecarfarin (0.05-0.3 mg/kg;口服;每日 2 次或每日 1 次;10-21 天) 每日 1 次给药会在比格犬中产生剂量依赖性抗凝作用。
Tecarfarin (0.5 mg/kg;口服;每日 1 次;连续 4 天) 可诱导比格犬产生稳定的抗凝作用,该作用可通过静脉输注新鲜冰冻血浆或皮下注射维生素 K1 完全逆转。
Tecarfarin (0.3 mg/kg 或调整剂量;口服;每日 1 次;连续 20 天) 在调整剂量以维持 PT 在 15-30 s 时,可诱导比格犬产生稳定的抗凝作用,且其抗凝效果和血浆水平不受 Amiodarone (MS-S57739) 联合用药的影响。

Animal Model: Beagle (adult female, 7-12 kg)
Dosage: 0.5 mg/kg
Administration: p.o.; daily; 6 days
Result: Increased prothrombin time (PT) from a pretreatment mean of 6.8 sec to 21.0 sec after 6 days of treatment.
Reduced levels of vitamin K-dependent coagulation factors II to 0.10-0.20, VII to < 0.01-0.01, IX to 0.15-0.23, and X to 0.03-0.11.
Left levels of factors V, VIII, and XI unaffected.
Animal Model: Mixed-breed (adult male and female, 20.0-22.7 kg, arterial and venous thrombosis induced by electrical injury plus flow-limiting stenosis)
Dosage: 0.05 mg/kg; 0.5 mg/kg
Administration: p.o.; daily; 4-7 days
Result: Increased PT from a baseline mean of 9.9 sec to 33.9 sec (3.4-fold elevation), and aPTT from a baseline mean of 11.6 sec to 17.6 sec (1.5-fold elevation) after treatment.
Prolonged mean time to arterial occlusion from 101 min (vehicle) to 159 min (tecarfarin), and mean time to venous occlusion from 68 min (vehicle) to 149 min (tecarfarin).
Prevented occlusive thrombi in 7 of 10 femoral arteries and 7 of 10 femoral veins.
Reduced mean arterial thrombus weight from 49.0 mg (vehicle) to 24.8 mg (tecarfarin).
Showed statistically significant differences between tecarfarin and vehicle groups.
Animal Model: New Zealand White (specific pathogen-free male, 3.5-4.5 kg, venous thrombosis induced by balloon catheter-induced endothelial denudation plus stasis)
Dosage: 1 mg/kg
Administration: p.o.; daily; 2 days
Result: Achieved a mean INR of 2.1 after 2 days of treatment.
Reduced mean thrombus radioactivity from 20.9% (saline control) to 2.3% (tecarfarin), with statistically significant difference.
Reduced mean thrombus weight (as a percentage of trapped blood weight) from 28.1% (saline control) to 5.1% (tecarfarin), with statistically significant difference.
Increased mean blood loss from ear incisions from 47.4 μL (saline control) to 249.9 μL (tecarfarin), with no statistically significant difference from control.
Animal Model: Beagle (female, 7-10 kg)
Dosage: 0.1 and 0.2 mg/kg
Administration: i.v.; continuous infusion; 9 days
Result: Reduced Factor X activity to 44% of control, Factor VII activity to 10% of control, and increased INR to 2.4 at 0.1 mg/kg.
Reduced Factor X activity to 36% of control, Factor VII activity to 5% of control, and increased INR to 4.1 at 0.2 mg/kg.
Reached steady-state plasma concentrations of ~60 ng/mL at 0.1 mg/kg and ~85 ng/mL at 0.2 mg/kg.
Animal Model: Beagle (2 males and 3 females per group, 7-12 kg)
Dosage: 0.05; 0.2; 0.25 and 0.3 mg/kg
Administration: p.o.; twice daily; 21 days (0.05 mg/kg); once daily; 11 days (0.2 mg/kg); once daily; 10 days (0.25 mg/kg); once daily; 14 days (0.3 mg/kg)
Result: Reduced Factor X activity to 50% of control, Factor VII activity to 5% of control, and increased INR to 2.4 at 0.2 mg/kg QD.
Reduced Factor X activity to 55% of control, Factor VII activity to 7% of control, and increased INR to 2.6 at 0.25 mg/kg QD.
Reduced Factor X activity to 50% of control, Factor VII activity to 2% of control, and increased INR to 3.7 at 0.3 mg/kg QD.
Animal Model: Beagle (1 male and 2 females per group)
Dosage: 0.5 mg/kg
Administration: p.o.; once daily; 4 days
Result: Increased PT to 17.3 s (FFP group) and 17.3 s (VitK1 group), with associated reductions in Factor VII and X activity consistent with an INR of 3.
Reversed PT to baseline within 15 minutes via intravenous FFP, and within 4 hours via subcutaneous vitamin K1.
Animal Model: Beagle (2 males and 4 females per group, 8-14 kg)
Dosage: 0.3 mg/kgor adjusted dose
Administration: p.o.; once daily; 20 days
Result: Increased PT to 26.3 s, reduced Factor VII activity by 100%, and reduced Factor X activity to 31% of baseline after 11 days of monotherapy.
Reached steady-state plasma concentrations of 57 ng/mL after 11 days of monotherapy.
Showed no significant effect on PT, Factor X activity, or plasma concentrations when co-administered with amiodarone.
性状 固体
颜色 White to off-white

化学信息

分子量 460.32
分子式 C21H14F6O5
CAS No. 867257-26-9
别名 ATI-5923

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 4 mg/mL (8.69 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 250 mg/mL (543.10 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1724 mL10.8620 mL21.7240 mL54.3100 mL
5 mM0.4345 mL2.1724 mL4.3448 mL10.8620 mL
10 mM0.2172 mL1.0862 mL2.1724 mL5.4310 mL
15 mM0.1448 mL0.7241 mL1.4483 mL3.6207 mL
20 mM0.1086 mL0.5431 mL1.0862 mL2.7155 mL
25 mM0.0869 mL0.4345 mL0.8690 mL2.1724 mL
30 mM0.0724 mL0.3621 mL0.7241 mL1.8103 mL
40 mM0.0543 mL0.2716 mL0.5431 mL1.3578 mL
50 mM0.0434 mL0.2172 mL0.4345 mL1.0862 mL
60 mM0.0362 mL0.1810 mL0.3621 mL0.9052 mL
80 mM0.0272 mL0.1358 mL0.2716 mL0.6789 mL
100 mM0.0217 mL0.1086 mL0.2172 mL0.5431 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 2 years; -20°C, 1 year。-80°C储存时,请在2年内使用, -20°C储存时,请在1年内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础